Tenax Therapeutics Faces Securities Class Action Lawsuit
A class action targets Tenax Therapeutics over alleged investor losses. The lead plaintiff deadline is December 28, 2026.
New York-based law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, seeking to recover damages on behalf of affected investors.
Investors who purchased TENX securities during the period between November 13, 2023, and August 7, 2026, may be eligible to participate in the litigation and recover losses stemming from that window. The class period spans nearly three years, suggesting the alleged misconduct or misrepresentations may have persisted over an extended stretch of the company's public disclosures.
Read more InsCorp Reports 12% Revenue Gain in Third Quarter 2026 →
The court-imposed deadline for investors seeking appointment as lead plaintiff is December 28, 2026. Lead plaintiff status allows an investor or group of investors to direct the litigation strategy on behalf of the broader class, and attorneys typically encourage early contact to preserve that option.
Securities class actions of this kind generally allege that a company or its executives made materially false or misleading statements that artificially affected the stock price, causing shareholders to suffer financial harm. The announcement did not detail the specific allegations underpinning the Tenax complaint beyond the class period and the damages sought.
Tenax Therapeutics is a clinical-stage biopharmaceutical company. Shareholders who believe they incurred losses during the specified period are encouraged to consult legal counsel to assess their eligibility and potential recovery options before the deadline passes. Continue reading at All Financial Services & Investing.
